President Biden revealed a proposal about a month ago to make coronavirus booster injections accessible to the vast majority of people in the United States eight months after they got their second dose of the virus. However, with less than a week before the plan is to be implemented, its specifics are still up in the air amid a chorus of opposition both inside and outside the administration.
Already, the White House has been obliged to postpone the distribution of booster vaccines to Moderna vaccine recipients, and it is now considering limiting the availability of a third injection to individuals who have received the Pfizer-BioNTech vaccine. Vaccines are available from Pfizer and BioNTech. Depending on what the two public health agencies determine in the future, the administration may be forced to alter its path once again, most likely restricting further vaccinations to elderly Americans and those who are especially susceptible to severe disease. increase.
Dr. Janet Woodcock, the acting commissioner of the Food and Drug Administration, and Dr. Rochelle P. Walensky, the director of the Centers for Disease Control and Prevention (CDC), among others, signed a statement announcing Vice President Biden’s health on Wednesday, according to Jen Psaki, the White House press secretary.
The Food and Drug Administration’s committee on third shots will meet on Friday to examine and vote on Pfizer-proposal BioNTech’s to provide third injections to individuals 16 and above. This week’s meeting of the C.D.C. panel is anticipated to take place. Officials at the agencies are not obliged to adopt the advice of their outside expert panels, although they do so in the vast majority of cases.
The Food and Drug Administration (FDA) may decide to cut down an authorisation based on the experts’ reactions to the data evaluation that was published on Wednesday by FDA officials. According to individuals involved with the talks, even if the C.D.C. accepts the application in its present form, it may prescribe boosters only for persons 65 and older or for those who are especially at risk, rather than for everyone.